Qualigen Therapeutics receives extension from Nasdaq hearings panel

Qualigen Therapeutic announced that on September 11, 2024, the Company received a notice from Nasdaq indicating that the Nasdaq Hearings Panel has granted an extension for the continued listing of the Company, subject to the Company evidencing compliance with all applicable criteria for continued listing on The Nasdaq Capital Market by November 19, 2024. The Company is diligently working to fulfill the requirements set forth by the Panel to ensure the Company’s continued listing on Nasdaq.